Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Esperion Therapeutics, Inc.NASDAQ: ESPR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$44.97M, compared with -$21M a year earlier. Trailing-twelve-month EBITDA was $39.9M.
Context
- EBITDA amounted to 15.8% of revenue in FY2025, up 13.6 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$218.52M (-442.1%) for the fiscal year ending Dec 2026, a slowdown from the +743.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$44.97M-152.1% QoQ
- Last fiscal yearDec 2025
- $63.87M+743.8% YoY
- LTMMar 2026
- $39.9M+145.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -114.1% | -769.4% | -655.3 pp |
| 1 year | +743.8% | -442.1% | -1186.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 63.87M USD
- Year-over-year change
- +743.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.87M | +743.8% |
| FY2024 | 2024-12-31 | 7.57M | +105.0% |
| FY2023 | 2023-12-31 | (150.11M) | +14.9% |
| FY2022 | 2022-12-31 | (176.35M) | +20.6% |
| FY2021 | 2021-12-31 | (222.14M) | — |
EBITDA vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +145.1% is the 3rd highest of 10, against a peer median of -14.3%.
- EBITDA amounts to 9.5% of revenue for ESPR, versus a peer median of 29.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $154.5M USD | +28.1% | +148.3% | 22.8% | |
| LTM Mar 2026 | $94.51M USD | +693.8% | — | 11.5% | |
| LTM Mar 2026 | CA$49.42M CAD | +201.3% | — | 5.3% | |
| LTM Mar 2026 | $39.9M USD | +145.1% | — | 9.5% | |
| LTM Mar 2026 | $27.5M USD | -56.2% | -11.5% | 29.3% | |
| LTM Mar 2026 | -$42.27M USD | -2.3% | — | — | |
| LTM Mar 2026 | -$51.63M USD | -40.6% | — | 102.7% | |
| LTM Mar 2026 | -$106.84M USD | -14.3% | — | 5818.9% | |
| LTM Mar 2026 | -$184.67M USD | -43.8% | — | — | |
| LTM Mar 2026 | -$229.35M USD | -87.3% | — | 261.2% | |
| Peer median (excluding ESPR) | — | -14.3% | +68.4% | 29.3% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.45M | 75.48M | 116.33M | 332.31M | 403.14M |
| Cost of Revenue | 14.22M | 26.97M | 43.27M | 68.6M | 129.22M |
| Gross Profit | 64.23M | 48.51M | 73.07M | 263.71M | 273.91M |
| Gross Margin | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| Research & Development | 105.98M | 118.93M | 86.11M | 46.24M | 47.85M |
| Selling, General & Admin | 184.99M | 109.08M | 142.52M | 163.07M | 165.79M |
| Operating Expenses | 290.96M | 228.01M | 228.63M | 209.31M | 213.64M |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| EBITDA | (222.14M) | (176.35M) | (150.11M) | 7.57M | 63.87M |
| EBITDA Margin | -283.2% | -233.7% | -129.0% | 2.3% | 15.8% |
| Operating Income | (226.73M) | (179.5M) | (155.56M) | 54.4M | 60.27M |
| Operating Margin | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.5M |
| Interest Expense | 46.35M | 56.81M | 58.98M | 59.25M | 84.6M |
| Other Income / Expenses | (42.38M) | (54.16M) | (53.69M) | (106.15M) | (81.11M) |
| Income Before Tax | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (20.84M) |
| Pre-Tax Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.84M |
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Net Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (Basic) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| EPS (Diluted) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| Weighted Avg Shares | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Weighted Avg Shares (Diluted) | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.